News

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15,…

2 years ago

Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)

– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of…

2 years ago

Syapse Enters Collaboration with Merck Using Real-World Evidence to Better Understand Cancers

SAN FRANCISCO and NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing…

2 years ago

Daré Bioscience to Participate in Two Upcoming Conferences

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

2 years ago

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

NEEDHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a late clinical…

2 years ago

Extendicare Announces September 2022 Dividend of C$0.04 per Share

MARKHAM, Ontario, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has…

2 years ago

Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused…

2 years ago

Veronica Todaro Joins VOZ Advisors as President and CEO

NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- VOZ Advisors is pleased to announce that Veronica Todaro has joined the…

2 years ago

RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital

Newly formed company founded by prominent Yale professors will advance development of novel RNA therapies and vaccine adjuvants for local…

2 years ago